ADMA vs NBIX: fair value comparison
ADMA Biologics, Inc. and Neurocrine Biosciences, Inc. · Updated 2026-10-19
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, NBIX currently sits closer to the top of our ranking by discount to fair value.
| ADMA | NBIX | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $10.68 | $135.71 |
| 12-month range | $7.60–$20.38 | $123.10–$185.50 |
| Rank by discount to fair value | #97 of 108 Healthcare | #5 of 108 Healthcare |
| Quality grade | A | A |
| Leverage | Low | Low |
| Margin trend | Expanding | Stable |
| Revenue growth | High | High |
| RSI zone | Overbought | Neutral |
| 50/200-day trend | Mixed | Mixed |
| DCF cross-check | Overvalued | Fairly Valued |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: ADMA fair value analysis · NBIX fair value analysis